[Author Disclosure: This content reflects the views of the author and is provided for informational purposes only. It does not constitute investment advice and is not a recommendation or endorsement by BioTech Funding Portal. Any investment decision should be based solely on the issuer’s official offering materials.]
Meet the person leading this: Chris Hopkins, CEO & Co-Founder.
Chris is a geneticist, biochemist, and entrepreneur who's spent his career at the intersection of science and company-building. He guided the acquisition of Knudra Transgenics by InVivo Biosystems, raised over $5M in venture capital and $7M in non-dilutive SBIR funding, licensed CRISPR technology in 2014 — shortly after it was invented — and holds 20+ patents.
He co-founded Glafabra around a body of work he didn't have to acquire: the FACTS trial data that he and his co-founders generated themselves.
What's one question you'd want to ask Glafabra's CEO directly? Drop it below — Chris is reading.
Follow the whole series: https://bit.ly/Glafabra-TTW
@Brian Christie @Neva West @Chris Hopkins @Tetsu Yung
Testing the Waters disclosure: We are considering a capital raise and are "Testing the Waters" under Regulation Crowdfunding. No money or other consideration is being solicited, and any that is sent in response will not be accepted. We cannot accept any offer to buy securities, and no part of the purchase price can be received until an offering statement is filed and only through the BioTech Funding Portal platform. Any indication of interest is non-binding and involves no obligation or commitment of any kind.
Register for FREE to comment or continue reading this article. Already registered? Login here.
0